Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1802 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Merck Serono Provides Data On Erbitux Trials

The analysis indicates that patients with KRAS wild-type tumors bearing a BRAF mutation also benefit from Erbitux treatment; therefore, KRAS remains the only validated, clinically predictive marker of